Overview
This program will examine current treatment standards for stage III non-small cell lung cancer (NSCLC). Advances in radiation therapy and novel systemic treatments will be highlighted. Recent data presented at ESMO 2017, ASTRO 2017 and WCLC 2017 that is most likely to impact patient care will be discussed. The status of immunotherapy for stage III disease will also be addressed.
In this session, the faculty will:
- Identify advances in radiation therapy for lung cancer that were shared at ESMO 2017, ASTRO 2017 and WCLC 2017;
- Outline how new, innovative approaches may be incorporated into clinical practice, and
- Discuss the clinical research developments that are likely to impact patient care and future clinical studies.
Moderator: Pr Françoise Mornex, MD, PhD
Département de Radiothérapie, Centre Hospitalier Lyon Sud, Lyon, France.
Maria Werner-Wasik, MD, FASTRO
Professor, Director of Clinical Research, Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Benjamin Besse, MD, PhD
Chairman, Department of Medical Oncology, Institut Gustave Roussy, Paris, France.
For any inquiries, please contact meetings@iaslc.org.
Moderator: Pr Françoise Mornex, MD, PhD
Département de Radiothérapie, Centre Hospitalier Lyon Sud, Lyon, France.
Maria Werner-Wasik, MD, FASTRO
Professor, Director of Clinical Research, Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Benjamin Besse, MD, PhD
Chairman, Department of Medical Oncology, Institut Gustave Roussy, Paris, France.
For any inquiries, please contact meetings@iaslc.org.